**Proteins** 



## **Product** Data Sheet

## **Theralizumab**

Cat. No.: HY-P9975 CAS No.: 906068-56-2

Target: CD28

Pathway: Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Theralizumab (TGN1412) is a humanized IgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis <sup>[1][2]</sup> .	
In Vitro	Theralizumab (5 $\mu$ g/mL, 4 days) increases CD4+ T-cell division in PBMCs following high-density (HD) preculture, and induces release of inflammatory cytokines <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Theralizumab (0.1-2 mg/kg, i.v.) induces lymphopenia and human cytokine release in humanized mice model <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Humanized mice model <sup>[3]</sup>
	Dosage:	0.1-2 mg/kg
	Administration:	i.v.
	Result:	Caused loss of hCD45+ cells of about 60% at 2 mg/kg from the peripheral blood.

## **REFERENCES**

- [1]. Thomas Hünig. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. FEBS J. 2016 Sep;283(18):3325-34.
- [2]. Dmitry Tyrsin, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. Jul-Aug 2016;34(4 Suppl 98):45-8.
- [3]. Weißmüller S, et al. TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One. 2016 Mar 9;11(3):e0149093.
- [4]. Hussain K, et al. Upregulation of FcyRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood. 2015 Jan 1;125(1):102-10.

Page 1 of 2 www.MedChemExpress.com  $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com